$KNSA News

Kiniksa Pharmaceuticals International, plc 2026 Q2 - Results - Earnings Call Presentation

Goldman Sachs Maintains Buy on Kiniksa Pharmaceuticals, Raises Price Target to $90

JP Morgan Maintains Overweight on Kiniksa Pharmaceuticals, Raises Price Target to $107

Canaccord Genuity Maintains Buy on Kiniksa Pharmaceuticals, Raises Price Target to $98

Wedbush Maintains Outperform on Kiniksa Pharmaceuticals, Raises Price Target to $99

Citigroup Maintains Buy on Kiniksa Pharmaceuticals, Raises Price Target to $100

Kiniksa Pharmaceuticals (NASDAQ:KNSA) Growth Stock Surges on Revenue Beat and Raised Guidance

Kiniksa Pharmaceuticals International, plc (KNSA) Q2 2026 Earnings Call Transcript

Kiniksa Pharmaceuticals Q2 EPS $0.30 Beats $0.27 Estimate, Sales $243.600M Beat $225.457M Estimate

Kiniksa Pharmaceuticals Raises FY2026 Sales Guidance from $930.000M-$945.000M to $980.000M-$995.000M vs $940.106M Est

Kiniksa Pharmaceuticals (NASDAQ:KNSA): A High-Growth Stock with Strong Technical Setup

Kiniksa Pharmaceuticals (NASDAQ:KNSA): A High Growth Momentum Stock With a Breakout Setup

Goldman Sachs Maintains Buy on Kiniksa Pharmaceuticals, Raises Price Target to $75

Kiniksa Pharmaceuticals (NASDAQ:KNSA) Qualifies as an Affordable Growth Stock With Strong Revenue and Earnings Momentum

Kiniksa Pharmaceuticals: Leader In Pericarditis Merits Hold Rating After Recent Gains

Wells Fargo Maintains Overweight on Kiniksa Pharmaceuticals, Raises Price Target to $74

Wedbush Maintains Outperform on Kiniksa Pharmaceuticals, Raises Price Target to $72

Kiniksa Pharmaceuticals International Plc (NASDAQ:KNSA) Presents a Compelling GARP Opportunity

Biotech Kiniksa Pushes Toward A Buy Zone With Blockbuster Drug Sales In View

Here's Why Momentum in Kiniksa Pharmaceuticals International, plc (KNSA) Should Keep going